Delivery Order SPE2DB24D2100-SPE2DB25FBGNE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,526.76 to AmerisourceBergen Drug Corp for 84 tablets of Xermelo 250 mg on August 25, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $5,526.76 to AmerisourceBergen Drug Corp for Xermelo 250 mg tablets (84-count supply) on August 14, 2025, with completion targeted for September 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $11,053.54 firm fixed price delivery order to AmerisourceBergen Drug Corp for Xermelo 250 mg tablets (84-count) on September 11, 2025, with an ultimate completion date of October 2, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $5,526.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xermelo 250 mg tablets (84-count units). This non-set-aside competitive award is scheduled for completion by August 11, 2025, with performance to be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency on September 11, 2025, for the supply of Xermelo 250 mg tablets (84-count units) under a firm fixed-price contract with a ceiling value of $11,053.54. The order is expected to be completed by October 2, 2025, and will be fulfilled from the vendor's corporate office in Conshohocken, Pennsylvania. This is a competitive award with no set-aside designation, reflecting AmerisourceBergen's capability to compete...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a for-profit organization, to provide the pharmaceutical product XERMELO 250 MG TABLET 84S. The contract, valued at $19,160.74, has an ultimate completion date of April 9, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division located in Conshohocken, Pennsylvania, is the prime contractor on this order. The contract is not associated with a larger vehicle and...
- This federal contract award, valued at $5,526.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XERMELO 250 MG TABLET 84S, a pharmaceutical product, and is a Firm Fixed Price Delivery Order. The contract has an ultimate completion date of March 31, 2025 and was awarded on March 10, 2025. This contract award is associated with a larger Indefinite Delivery...
- This delivery order for $9,295.70, awarded by the Defense Logistics Agency to Amerisourcebergen Drug Corporation, is for the purchase of 84 boxes of XERMELO 250 MG tablets with a completion date of November 6, 2023. The contract has a firm fixed price and will be performed in Conshohocken, Pennsylvania by Amerisourcebergen Drug Corporation's Corporate Office as the prime contractor. No set-aside designation was used for this procurement. The Defense Logistics Agency supports America's armed...
- This federal contract award, with an ID of SPE2DB22D2206|SPE2DB25FGB40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,526.76 firm fixed-price delivery order contract, which runs through April 2, 2025, is for the supply of XERMELO 250 MG TABLET 84S, a medical product. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a...
- The Defense Logistics Agency awarded a $27,841.82 firm fixed price delivery order to AmerisourceBergen Drug Corp for 4569617740 ORSERDU 345 mg tablets (30-count units) on September 28, 2025, with an ultimate completion date of October 20, 2025. This non-set-aside competitive award leverages AmerisourceBergen's indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.9 million through December 2026. The vendor, headquartered in Conshohocken,...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBGNEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Xermelo 250 mg tablets (84-count units) with a ceiling value of $5,526.76. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of October 14, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026. The delivery order represents a continuation of AmerisourceBergen Drug Corp's ongoing role as a critical vendor within the Defense Logistics Agency's Medical Supply Chain. The company's federal contract portfolio demonstrates extensive experience fulfilling military and veteran healthcare pharmaceutical needs through competitively awarded agreements with firm fixed pricing structures. DLA Troop Support is implementing the Pharmaceutical Prime Vendor Global Program Generation V initiative, which envisions multiple regional awards among several contractors to optimize pharmaceutical distribution and support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 9/22/25 |